Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor

Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor

US Patent 11116795 · Granted Sep 14, 2021

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Fully-human T-cell receptor specific for the 369-377 epitope derived from the He2025
Treatment of a canine CD20 positive disease or condition using a canine CD20-spe2025
Treatment of a canine CD20 positive disease or condition using a canine CD20-spe2025
Treatment of a canine CD20 positive disease or condition using a canine CD20-spe2025
Treatment of a canine CD20 positive disease or condition using a canine CD20-spe2025
Use of trans-signaling approach in chimeric antigen receptors2025
Methods for improving the efficacy and expansion of immune cells2025
Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against 2025
Human alpha-folate receptor chimeric antigen receptor2024
Canine monoclonal antibodies against canine cytotoxic T lymphocyte associated pr2024
Universal immune receptor expressed by T cells for the targeting of diverse and 2024
Methods for improving the efficacy and expansion of chimeric antigen receptor-ex2024